top of page

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Updated: Feb 15, 2022

The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1.


  • Subsequent Therapy for ROS1 Rearrangement-Positive Metastatic NSCLC (NSCL-24)

  • Lorlatinib (category 2A) added as a treatment option, after progression on crizotinib or ceritinib.


56 views0 comments
bottom of page